Drug Therapies for the Management of Sickle Cell Disease
[version 1; peer review: 1 approved]

Parul Rai 1, Kenneth I. Ataga 2

1Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA
2Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, TN, USA

Abstract
Sickle cell disease (SCD) afflicts millions of people worldwide but is referred to as an orphan disease in the United States. Over the past several decades, there has been an increasing understanding of the pathophysiology of SCD and its complications. While most individuals with SCD in resource-rich countries survive into adulthood, the life expectancy of patients with SCD remains substantially shorter than for the general African-American population. SCD can be cured using hematopoietic stem cell transplantation and possibly gene therapy, but these treatment approaches are not available to most patients, the majority of whom reside in low- and middle-income countries. Until relatively recently, only one drug, hydroxyurea, was approved by the US Food and Drug Administration to ameliorate disease severity. Multiple other drugs (L-glutamine, crizanlizumab, and voxelotor) have recently been approved for the treatment of SCD, with several others at various stages of clinical testing. The availability of multiple agents to treat SCD raises questions related to the choice of appropriate drug therapy, combination of multiple agents, and affordability of recently approved products. The enthusiasm for new drug development provides opportunities to involve patients in low- and middle-income nations in the testing of potentially disease-modifying therapies and has the potential to contribute to capacity building in these environments. Demonstration that these agents, alone or in combination, can prevent or decrease end-organ damage would provide additional evidence for the role of drug therapies in improving outcomes in SCD.

Keywords
Sickle cell disease, Treatment, Novel Drugs, Drug Development, Clinical Trials
Corresponding author: Kenneth I. Ataga (kataga@uthsc.edu)

Author roles: Rai P: Investigation, Writing – Original Draft Preparation; Ataga KI: Conceptualization, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: KIA has served on clinical advisory boards and/or served as a consultant for Global Blood Therapeutics, Novartis, Emmaus Life Sciences, Editas Medicine, and Novo Nordisk. PR has no competing interests.

Grant information: This work is supported by an award from the US Food and Drug Administration - R01FD006030 (KIA).

Copyright: © 2020 Rai P and Ataga KI. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Rai P and Ataga KI. Drug Therapies for the Management of Sickle Cell Disease [version 1; peer review: 1 approved] F1000Research 2020, 9(F1000 Faculty Rev):592 https://doi.org/10.12688/f1000research.22433.1

First published: 11 Jun 2020, 9(F1000 Faculty Rev):592 https://doi.org/10.12688/f1000research.22433.1
**Introduction**

Although referred to as an orphan disease in the United States (US), sickle cell disease (SCD) affects millions of individuals worldwide, with the vast majority residing in sub-Saharan Africa and India. SCD is characterized by the presence of sickle hemoglobin (HbS), hemolytic anemia, vaso-occlusive complications, and cumulative end-organ damage. The mortality rate associated with SCD in sub-Saharan Africa remains high, with an estimated 50 to 90% of children dying before the age of 5. However, the majority of children with SCD in resource-rich countries live to adulthood. Despite increased survival to adulthood, individuals with SCD in resource-rich nations continue to have a shorter life expectancy than the general population. There has been substantial progress with the use of allogeneic bone marrow transplantation as a curative therapy in SCD, and increasing evidence supports the curative potential of gene therapy and gene editing.

This review will focus on approaches to develop drug therapies in SCD, ongoing and recently completed trials, and our perspective on the use of approved drugs.

**Pathophysiology**

The development of effective therapies for SCD depends on an adequate understanding of its pathophysiology. Although the pathophysiology of SCD is complex and involves multiple pathways, the primary event is due to the polymerization of HbS following deoxygenation. The rate and extent of polymer formation depends on the degree and duration of HbS deoxygenation, presence of fetal hemoglobin (HbF), and the intracellular concentration of HbS. Clinical manifestations of SCD appear to be driven by two major pathophysiological processes: vaso-occlusion with ischemia-reperfusion injury and hemolytic anemia. Vaso-occlusion occurs because of adhesive interactions of leukocytes and sickle RBCs with the endothelium causing microvascular obstruction and subsequent tissue ischemia. These episodes of vascular obstruction are followed by the restoration of blood flow, which promotes further tissue injury by reperfusion. The inflammatory cascade resulting from ischemia-reperfusion is amplified by the activation of CD1d-restricted invariant natural killer T (iNKT) cells. The release of free plasma hemoglobin following intravascular hemolysis results in direct scavenging of nitric oxide (NO), as well as the generation of reactive oxygen species, powerful scavengers of NO. NO is usually produced by the endothelium and regulates basal vasodilator tone as well as inhibits the activation of platelets and the coagulation system and the transcriptional expression of nuclear factor κB (NFκB)-dependent adhesion molecules, such as vascular cell-adhesion molecule-1, intercellular cell-adhesion molecule-1, and selectins. HbS polymerization as well as its multiple downstream consequences, including endothelial cell injury, endothelial dysfunction, increased oxidant stress, inflammation, and coagulation and platelet activation, are therapeutic targets in SCD (Figure 1). SCD has been dichotomized into two overlapping sub-phenotypes: viscosity-vaso-occlusion (higher hemoglobin levels, possibly increased blood viscosity, and complications such as osteonecrosis, acute chest syndrome, and acute pain crisis) and hemolysis-endothelial dysfunction (increased hemolysis with lower hemoglobin levels and higher levels of hemolytic markers, including reticulocyte...
count and serum lactate dehydrogenase, and complications such as leg ulcers, priapism, stroke, and possibly pulmonary hypertension\(^\text{19}\). While somewhat simplistic, this classification is useful to understand the pathobiology of disease complications and may provide guidance on the effects of therapies on disease-related complications. The pathophysiology of SCD has been reviewed more extensively elsewhere\(^\text{20-22}\).

**Drug therapies for sickle cell disease**

Despite an improved understanding of the pathophysiology of SCD, available drug treatments remain limited. For many years, hydroxyurea was the only drug available to modify the severity of SCD\(^\text{23}\). However, there has been progress in the development of drug therapies with recent approvals of L-glutamine, crizanlizumab, and voxelotor by the US Food and Drug Administration (FDA)\(^\text{24-26}\). Based on our current understanding of SCD pathophysiology, there are multiple possible approaches to treating the disease and its complications, including inhibition of HbS polymerization and amelioration of multiple downstream sequelae of HbS polymerization.

**Inhibition of sickle hemoglobin polymerization**

Therapeutic approaches targeting HbS polymerization, including 1) blocking intermolecular contacts in the sickle fiber, 2) induction of HbF synthesis, 3) reduction of intracellular HbS concentration, 4) increase in oxygen affinity, and 5) reduction of the concentration of 2,3-diphosphoglycerate, have been described\(^\text{27}\). Table 1 lists ongoing studies of anti-sickling agents in SCD.

**Induction of fetal hemoglobin.** High levels of HbF ameliorate the severity of SCD\(^\text{28,29}\). Hydroxyurea strongly induces HbF\(^\text{30}\), although the mechanisms by which it does so are still unclear\(^\text{31-33}\). Hydroxyurea improves erythrocyte deformability, lowers hemolysis, decreases circulating leukocytes and reticulocytes\(^\text{34}\), reduces adhesion receptor expression\(^\text{35-38}\), and is an NO donor\(^\text{39,40}\). In two placebo-controlled, phase III trials, hydroxyurea significantly reduced the frequency of vaso-occlusive crises, acute chest syndrome, blood transfusion requirement, and hospitalizations in adults and children with SCD\(^\text{31,41}\). Treatment with low, fixed weight-based dosing of hydroxyurea (10 mg/kg daily) also decreased the frequency of SCD-related complications with low toxicity\(^\text{42,43}\). Hydroxyurea further ameliorates SCD morbidity by decreasing the risk of stroke and chronic kidney disease\(^\text{44,45}\) and may reduce mortality in SCD\(^\text{46-49}\). Recent studies to optimize hydroxyurea therapy are exploring dose maximization via pharmacokinetics-based dosing\(^\text{50-54}\). Despite its multiple benefits, a substantial number of patients on hydroxyurea may not obtain an adequate clinical response.

Inhibitors of epigenetic enzymes which repress \(\gamma\)-globin genes, including DNA methyltransferase (DNMT1), histone deacetylases, and lysine-specific demethylase (LSD-1), and \(\gamma\)-globin gene co-activator agonists are being evaluated in SCD. Decitabine (5-aza-2’-deoxycytidine), a DNA hypomethylating agent which depletes DNMT1, increased HbF and total hemoglobin levels at non-cytotoxic doses in patients who had no responses to hydroxyurea\(^\text{55}\). However, it has a very short plasma half-life and negligible oral bioavailability due to rapid inactivation by cytidine deaminase (CDA)\(^\text{56}\). The combination of escalating doses of oral decitabine and an oral CDA inhibitor, tetrahydouridine (THU), was well tolerated, and the highest tested dose increased HbF, doubled F-cells by approximately 80% of total RBCs, increased total hemoglobin, and decreased biomarkers of hemolysis, coagulation activation, and inflammation\(^\text{57}\).

Histone deacetylase (HDAC) inhibitors increase HbF levels\(^\text{58-63}\). Although treatment with intermittent doses of sodium butyrate produced sustained increases in HbF, F-cells, and total hemoglobin\(^\text{59}\), the orally available sodium dimethyl butyrate (HQK-1001) did not significantly increase HbF and appeared to result in more pain crisis compared with placebo\(^\text{60}\). A phase II study of the global HDAC inhibitor vorinostat was terminated early owing to poor accrual. Selective HDAC1/2 inhibition with ACY-957 increased HbF \textit{in vitro} and represents a promising therapeutic approach with a better safety profile\(^\text{61}\). Based on the success of the LSD-1 inhibitors RN-1 and ORY-3001 in increasing HbF and F-cells in preclinical studies\(^\text{62-67}\), INC059872 was investigated (NCT03132324). However, this phase I study was terminated early for business reasons. Pomalidomide, a third-generation immunomodulatory drug, produced modest increases of HbF, augmented erythropoiesis, and preserved bone marrow function following 8 weeks of treatment in transgenic sickle mice\(^\text{68}\). Pomalidomide appeared to increase HbF and total hemoglobin only at the highest dose or with greater than 6 months of exposure\(^\text{69}\). The safety and efficacy of increasing the expression of \(\gamma\)-globin gene co-activators—FOXO3 agonist\(^\text{70}\) (metformin [NCT02983129]), nuclear factor-like-2 (Nrf2) agonist\(^\text{71}\) (dimethyl fumarate), and SIRT1\(^\text{72}\)—to augment HbF levels are being explored.

**Allosteric modification of sickle hemoglobin to its high-oxygen affinity R-state.** Voxelotor, recently approved under the FDA’s accelerated approval program, is an orally bioavailable small molecule which binds to \(\alpha\)-globin chains of hemoglobin, increases hemoglobin oxygen affinity, and stabilizes the oxyhemoglobin state\(^\text{73}\). Early studies showed a reduction in markers of hemolysis, with a rapid rise in hemoglobin by day 15\(^\text{54}\). This response was not accompanied by worsening tissue hypoxia, based on serum erythropoietin levels and change in oxygen consumption (VO\(_2\) max), even in participants receiving daily doses of 1,000 mg for 28 days and 900 mg for at least 90 days. Furthermore, voxelotor has been shown to reduce blood viscosity \textit{in vitro}\(^\text{75}\). In a multicenter, phase III study of patients 12 to 65 years of age, randomly assigned to once-daily oral voxelotor doses of 1,500 mg, 900 mg, or placebo, a significantly higher percentage of subjects on 1,500 mg had a hemoglobin response of 1.0 g/dL at 24 weeks compared with placebo\(^\text{76}\). In addition, subjects on the 1,500 mg dose saw significant reductions in indirect bilirubin and reticulocyte counts from baseline. A dose-dependent increase in hemoglobin following treatment with voxelotor was not accompanied by an increase in pain crisis rate. As this trial was not enriched for subjects with frequent pain crises, appropriately designed studies
| Mechanism                        | Drug Name | Sponsor                     | NCT number                | Clinical phase/ status | Number/age       | Objective                                                                                     |
|---------------------------------|-----------|-----------------------------|---------------------------|------------------------|------------------|----------------------------------------------------------------------------------------------|
| HbF induction                   | Nicotinamide vs. THU and decitabine | EpiDestiny, Inc; NIH; NHLBI | NCT04255818 Phase I Recruiting | 20±18 years          | Oral nicotinamide vs. THU-decitabine for 12 weeks followed by combination for another 12 weeks | Compare effect of oral nicotinamide vs. THU-decitabine on hemoglobin level at week 12       |
|                                |           |                             |                           |                        |                  |                                                                                               |
|                                |           |                             |                           |                        |                  |                                                                                               |
|                                |           |                             |                           |                        |                  |                                                                                               |
|                                |           |                             |                           |                        |                  |                                                                                               |
| Allosteric modifier (to the R-state) | Voxelotor (formerly GBT440) | Global blood therapeutics | NCT03943615 Approved for marketing | ≥18 years | Oral, ≥12 years | To provide early access to patients without alternative treatment options                      |
|                                |           |                             |                           |                        |                  |                                                                                               |
|                                |           |                             |                           |                        |                  |                                                                                               |
|                                |           |                             |                           |                        |                  |                                                                                               |
| Allosteric activator of RBC pyruvate kinase | AG-348 (Milapril sulfate) | NHLBI | NCT04200165 Phase I Recruiting | 60/18–55 years | Oral, with two dose escalations after 2 weeks | Safety and tolerability, SCD-related complications                                      |
|                                |           |                             |                           |                        |                  |                                                                                               |
|                                |           |                             |                           |                        |                  |                                                                                               |
|                                |           |                             |                           |                        |                  |                                                                                               |
| RBC ion transport channels     | Memantine (NMDAR antagonist) | HaEmek Medical Center, Israel | NCT04247218 Phase I Recruiting | 40±10 years | Oral, once daily for 1 year | Safety, frequency of hospitalizations, duration of hospitalizations, analgesic use, transfusion requirement, QOL measures |
|                                |           |                             |                           |                        |                  |                                                                                               |

HbF, fetal hemoglobin; QOL, quality of life; NHLBI, National Heart, Lung, and Blood Institute; NMDAR, N-methyl-D-aspartate receptor; RBC, red blood cell; SCD, sickle cell disease; TCD, transcranial doppler; THU, tetrahydrouridine; VOC, vaso-occlusive crisis.
of patients with frequent pain episodes are needed to determine the effect of voxelotor on reducing such crises. Open-label extension studies to assess the long-term effects of voxelotor are ongoing.

5-hydroxymethyl-2-furfural (SHMF, Aes-103) interacts allosterically with HbS, increasing oxygen affinity and decreasing HbS polymerization and RBC sickling during hypoxia. A phase I trial, with oral doses of up to 4,000 mg, showed no significant side effects\(^5\), but a phase II trial was terminated early because of unbinding of drug groups (NCT01987908). FT-4202, a novel selective activator of RBC pyruvate kinase, decreases intracellular 2,3-diphosphoglycerate levels, with a resulting increase in hemoglobin-oxygen affinity. It demonstrated a favorable safety profile in healthy individuals\(^6\) and is being investigated in a phase I study in SCD (NCT03815695).

The oxygen delivery therapeutic agents sanguinate (pegylated bovine carboxyhemoglobin) and MP4CO (pegylated human carboxyhemoglobin) are dual transfer agents which release carbon monoxide when delivering oxygen to hypoxic tissues. They stabilize HbS in its R-state and appear to exhibit anti-inflammatory and anti-apoptotic activity by induction of Nrf2 and heme oxygenase-1\(^7\). Sanguinate had an acceptable safety profile\(^8\). A phase II study evaluating its efficacy during acute pain crisis was recently completed (NCT02411708).

**Increase red blood cell hydration.** The inverse relationship between HbS concentration and delay time suggests that even small decreases in intracellular HbS might be beneficial\(^9\). Semicapoc selectively blocks the calcium-activated, potassium efflux (Gardos) channel and improves anemia and hemolysis in SCD\(^10\). Despite improvements in anemia and hemolysis, a phase III trial showed no significant decrease in the rate of pain crises compared to placebo\(^11\). Similarly, studies of agents that block the potassium-chloride co-transport channel showed no clinical benefits\(^12\). SCD101, a botanical drug with an unclear anti-sickling mechanism which might involve dilution of HbS by affecting the RBC membrane, was well tolerated in a phase Ib study, with a decrease in chronic pain and fatigue and improvement in leg ulcers\(^13\).

**Targeting downstream sequelae of sickle hemoglobin polymerization**

**Antioxidant therapy.** Agents that upregulate antioxidant and/or reactive oxygen species scavenging processes have been evaluated in SCD. Glutamine, a conditionally essential amino acid, is a precursor for nicotinamide adenine dinucleotide (NAD) and improves NAD redox potential. In a randomized, multicenter trial of 230 patients with HbSS or HbSβ\(^-\)thalassemia, L-glutamine significantly reduced the number of pain crises, hospitalizations, cumulative hospital days, and frequency of acute chest syndrome compared with placebo\(^14\). However, the effect size of L-glutamine in reducing pain crises was relatively small, with only a 25% reduction in the median number of pain crises. L-glutamine was well tolerated, although low-grade nausea, non-cardiac chest pain, fatigue, and musculoskeletal pain occurred more frequently than with placebo. Despite some concerns related to the high dropout rate in the trial (36% L-glutamine arm; 24% placebo arm), L-glutamine was approved by the FDA to reduce the acute complications of SCD in patients 5 years and older\(^15\).

In an open-label pilot trial of oral N-acetylcysteine (NAC), treatment with either 1,200 mg or 2,400 mg daily for 6 weeks increased whole blood glutathione levels and decreased erythrocyte outer membrane phosphatidylserine exposure, plasma levels of advanced glycation products, and cell-free hemoglobin in both groups\(^16\). A randomized, placebo-controlled, double-blind trial of NAC at 600 mg twice daily for 6 months did not decrease the rate of SCD-related pain days per patient year, vaso-occlusive crises, hospital admission days, number of admissions, or days with home analgesic use compared with placebo\(^17\). The safety and efficacy of NAC, administered at a higher dose during pain crisis, is being explored in a phase II study (NCT01800526) (Table 2).

**Anti-adhesive therapy.** Agents targeting adhesion of blood cells to the endothelium have been investigated in SCD. Crizanlizumab, a humanized monoclonal anti-P-selectin antibody, was recently approved for use in patients 16 years and older for the prevention of vaso-occlusive crises\(^18\) based on results of a randomized, double-blind, phase II study which evaluated the benefit of 2.5 mg/kg or 5 mg/kg doses versus placebo. Significantly lower median crisis rate, longer median times to first and second crises, and lower median rate of uncomplicated crises per year were observed with high-dose crizanlizumab compared with placebo following a 52-week treatment period\(^19\). Multiple other studies of crizanlizumab are ongoing (Table 2).

Purified poloxamer 188, a nonionic block copolymer surfactant with hemorheologic and antithrombotic properties, was previously shown to significantly decrease the duration of pain episodes, especially in children and patients on hydroxyurea\(^20\). However, a more recent phase III study in children and adults reported no significant effect of purified poloxamer 188 (vepoloxamer or MST-188) on duration of vaso-occlusive crises compared with placebo\(^21\). Rivipansel sodium (formerly GMI-1070) is a small-molecule pan-selectin inhibitor that binds to E-, P-, and L-selectin\(^22\). In a randomized, double-blind, adaptive, phase II trial, treatment with rivipansel during pain crisis produced a significant reduction in the mean cumulative intravascular opioid analgesic use compared to placebo\(^23\). However, despite the promising phase II trial results, the recently completed multicenter phase III RESET trial failed to meet its primary (time to readiness for discharge) and key secondary (time to discharge, cumulative intravenous opioid utilization, and time to discontinuation of intravenous opioids) efficacy endpoints\(^24\).

Heparins inhibit adhesive interactions via P-selectin\(^25,26\). Tinzaparin, a low-molecular-weight (LMW) heparin, at therapeutic dose reportedly decreased the number of hospital days, the number of days with pain crisis, and the number of days with the most severe pain scores compared with placebo\(^27\). Sevuparin, a derivative of LMW heparin, which retains the P-selectin-binding domain of heparin but largely lacks anticoagulant properties, binds to P- and L-selectins,
### Table 2. Ongoing clinical trials of anti-adhesion agents and antioxidants in sickle cell disease.

| Mechanism                  | Drug          | Sponsor                                | NCT number (study acronym) | Clinical phase/status | Intervention                                      | Number/age | Objective                                                                 |
|----------------------------|---------------|----------------------------------------|----------------------------|-----------------------|--------------------------------------------------|------------|---------------------------------------------------------------------------|
| P-selectin antagonist      | Crizanlizumab | Novartis Pharmaceuticals               | NCT03264989 (SOLACE-adults) | Phase II Active, not recruiting | IV infusion, open-label                           | 57/16–70 years | Pharmacokinetics, pharmacodynamics, safety, and efficacy                  |
|                            |               |                                        | NCT03814746 (STAND)         | Phase III Recruiting    | IV infusion every 2 weeks for 1st month and then monthly for 1 year | 240≥12 years | Compare efficacy and safety of 5 mg/kg and 7.5 mg/kg doses with placebo |
|                            |               |                                        | NCT04053764 (STEADFAST)     | Phase II Recruiting    | IV infusion every 2 weeks for 1st month and then every 4 weeks for 51 weeks + SoC vs. SoC alone | 170≥16 years | Evaluating effect on kidney function (albumin-creatinine ratio, protein-creatinine ratio, estimated glomerular filtration rate) |
|                            |               |                                        | NCT03938454 (SPARTAN)       | Phase II Recruiting    | IV infusion every 2 weeks for 1st month and then every 4 weeks x 51 weeks | 56≥16 years | Evaluate efficacy in priapism, uncomplicated VOC events                   |
|                            |               |                                        | NCT03474965                 | Phase II Recruiting    | IV infusion every 2 weeks for 1st month and then every 4 weeks | 100/6 months—<18 years | Evaluate pharmacokinetics, pharmacodynamics, safety, and effect on VOC events |
| Blockade of fcyRIII receptors | IVIG          | Albert Einstein College of Medicine    | NCT01757418                | Phase I–II Recruiting | Single dose of IVIG vs. placebo given within 24 hours of hospitalization | 94/12–65 years | Length of VOC, total opioid use, time to end of VOC, in vitro adhesion studies |
| Antioxidant (increased glutathione) | NAC          | Bloodworks                             | NCT01800526                | Phase I/II Enrolling by invitation | IV or oral, NAC Part 1: two doses of IV infusion over 8 hours 4 weeks apart or oral NAC for 4 weeks Part 2 (during VOC): IV infusion every 6 hours for 5 days | 20≥18 years | Evaluate effect on vWF activity, measures of hemolysis and oxidation In Part 2, evaluate efficacy during VOC |

IV, intravenous; IVIG, intravenous gammaglobulin; NAC, N-acetylcysteine; SoC, standard of care; VOC, vaso-occlusive crisis; vWF, von Willebrand factor activity.
thrombospondin, fibronectin, and von Willebrand factor, inhibits the adhesion of sickle RBCs to stimulated cultured endothelial cells in vitro, and prevents vaso-occlusion with normalization of blood flow in a mouse model of vaso-occlusion\(^\text{106}\). A recently completed randomized, double-blind, placebo-controlled trial found that, although safe, sevuparin did not significantly reduce the time to resolution of vaso-occlusive crisis\(^\text{103}\). A phase II feasibility study of therapeutic-dose unfractionated heparin (NCT02098993) was recently terminated for poor enrollment, but a phase III, randomized, placebo-controlled study of tinzaparin in acute chest syndrome is ongoing (NCT02580773).

Intravenous immunoglobulin (IVIG) binds to FcγRIII receptors, inhibits neutrophil adhesion to the endothelium, reduces RBC capture by leukocytes, and reduces Mac-1 activity due to recruitment of Src homology 2-containing tyrosine phosphatase-1\(^\text{104}\). IVIG was tolerated at doses of up to 800 mg/kg during acute vaso-occlusive crises and decreased Mac-1 function from baseline\(^\text{105}\). A phase II clinical trial of IVIG during acute pain episodes is ongoing (NCT01757418).

**Anti-inflammatory agents.** Multiple approaches to down-regulate inflammatory pathways have been evaluated. Initial clinical responses with the use of steroids for pain crisis and acute chest syndrome were followed by “rebound” pain episodes and re-admissions after treatment discontinuation\(^\text{106,107}\). Inhaled corticosteroids did not significantly reduce the morbidity of acute chest syndrome in a retrospective cohort study\(^\text{108}\), but inhaled mometasone significantly reduced daily pain diary scores and levels of soluble vascular adhesion molecule-1 over the 16-week treatment period in another single-center, placebo-controlled trial\(^\text{109}\).

The activation of iNKT cells is downregulated by the activation of adenosine A2A receptors (A2AR)\(^\text{110}\). Regadenoson, a partially selective A2AR agonist, was reportedly safe but did not decrease length of hospital stay, total opioid use, or pain scores compared to placebo during pain crises\(^\text{111,112}\). In addition, there were no significant differences between regadenoson and placebo regarding the number of patients exhibiting a greater than 30% reduction in activated iNKT cells. The anti-iNKT monoclonal antibody NKTT120 resulted in rapid, specific, and continuous iNKT cell depletion in a single-ascending-dose study\(^\text{113}\), but further studies are required to determine its long-term safety and efficacy.

Statins have benefits independent of their cholesterol-lowering effect. In a pilot study, simvastatin was well tolerated, increased levels of NO metabolites, and decreased C-reactive protein (CRP) and interleukin-6 levels\(^\text{114}\). Daily treatment with simvastatin for 3 months significantly reduced pain crises, oral analgesic use, and levels of high-sensitivity CRP, soluble E-selectin, soluble ICAM-1, soluble ICAM-3, and VEGF\(^\text{115}\), providing supporting data for conduct of a placebo-controlled trial. Atorvastatin was well tolerated in a pilot study but did not improve endothelial function or decrease albuminuria\(^\text{116,117}\).

Long-chain omega-3 polyunsaturated fatty acids such as eicosapentaenoic acid (EPA [n-3]) and docosahexaenoic acid (DHA [n-6]) provide benefit to individuals with chronic inflammatory disorders. In a randomized, single-center study, daily omega-3 administered in capsule form significantly lowered the occurrence of vaso-occlusive events, severe anemia, blood transfusion requirements, and school absence compared with placebo\(^\text{118}\). More recently, a randomized, placebo-controlled study of different doses of SC411, a novel DHA ethyl ester formulation with high DHA bioavailability, found it was well tolerated, with significant reductions in d-dimer and E-selectin and an increase in hemoglobin\(^\text{119}\). SC411 also significantly reduced electronic diary-recorded pain episodes, analgesic use at home, and days absent from school but did not significantly lower pain crises in the pooled active groups compared to placebo.

Preliminary results suggest that the monoclonal anti-IL1β antibody canakinumab (ACZ885) is well tolerated and not associated with major side effects in SCD\(^\text{119}\).

**Anticoagulant and antiplatelet therapies.** With abundant evidence that SCD is a hypercoagulable state\(^\text{120-125}\), combined with data that coagulation and platelet activation may play roles in disease pathophysiology\(^\text{120-124}\), multiple studies have evaluated the effects of anticoagulants and antiplatelet agents in SCD. Although treatment with the LMW heparin tinzaparin produced more rapid resolution of pain crisis and shorter duration of hospitalization than placebo\(^\text{120}\), it is uncertain whether the reported beneficial effects were a result of its anticoagulant or anti-adhesive effects. The results of a pilot study of the direct oral anticoagulant rivaroxaban in SCD are awaited (NCT02072668).

Multiple relatively small studies of aspirin have reported modest benefit at best\(^\text{126-128}\), although one study reported an increase in oxygen affinity, hemoglobin level, and RBC lifespan\(^\text{129}\). A pilot study of the glycoprotein Ib/IIa inhibitor eptifibatide showed that it was safe during acute pain episodes but did not reduce the time to resolution of such episodes\(^\text{129}\). Ticlopidine, a P2Y\(_{12}\) ADP-receptor antagonist, reportedly decreased the number of pain episodes, mean duration of pain episodes, and severity of such episodes\(^\text{129}\). However, a more recent phase III trial of prasugrel, a newer generation P2Y\(_{12}\) receptor blocker, showed no significant reduction of the frequency of pain episodes in children with SCD\(^\text{130}\). Ticagrelor, a reversible P2Y\(_{12}\) receptor blocker, was well tolerated in children\(^\text{131}\) and young adults\(^\text{132}\) but had no beneficial effects on pain. A Phase III study to determine the efficacy of ticagrelor in reducing vaso-occlusive crises in children is ongoing\(^\text{133}\) (Table 3).

**Nitric oxide and related agents.** With the role of hemolysis in NO scavenging and subsequent endothelial dysfunction, NO and related agents may be beneficial in SCD\(^\text{134}\). Inhaled NO did not improve time to resolution of pain crisis, length of hospitalization, opioid usage, or rate of acute chest syndrome compared with placebo\(^\text{135}\). In another study, inhaled NO did not reduce the rate of treatment failure in adult patients with mild

---

\(\text{F1000Research 2020, 9(F1000 Faculty Rev):592 Last updated: 11 JUN 2020}\)
### Table 3. Ongoing clinical trials of anticoagulants, antiplatelet agents, anti-inflammatory agents, and nitric oxide-related drugs in sickle cell disease.

| Mechanism | Drug | Clinical phase | Objective | Number/age | Sponsor | Intervention | NCT number (study acronym) | Recruitment status | Status | NCT number (TASC) |
|-----------|------|----------------|-----------|------------|---------|--------------|---------------------------|-------------------|--------|------------------|
| Anticoagulant, antiplatelet | Ticagrelor | Phase I/II | Safety, pharmacokinetics | 200/18–70 years | AstraZeneca | Oral, once daily vs. placebo | NCT02973360 (ON-TIME) | Recruiting | Active, not recruiting | NCT03805581 (HESTIA3) |
| Anti-inflammatory | Docosahexaenoic acid (SC411) | Phase II | Safety, pharmacokinetics, effect on VOC | 480/10–19 years | Micelle BioPharma | Oral, daily 12 weeks vs. placebo | NCT02525107 (SCOT study) | Active, not recruiting | Recruiting | NCT03285178 (IMPROVE2) |
| Anti-inflammatory | Canakinumab | Phase III | Effect on VOC, including total hospitalizations, SCD-related complications, functional echocardiography-derived tricuspid regurgitant jet velocity | 70/18–55 years | Novartis | Subcutaneous, monthly for 6 months vs. placebo, followed by 49-month open-label extension | NCT01202812 (TASC) | Active, not recruiting | Recruiting | NCT04053803 (SC01 study) |
| Anti-inflammatory | Arginine | Phase III | Increased NO production | 70/18–55 years | Emory University | Oral, daily for 24 weeks vs. placebo | NCT03615924 (IMRA study) | Enrolling by invitation | Recruiting | NCT02447874 (IMR-687) |
| Increased NO production | Rifaximin (antibiotic, neutrophil) | Phase II | Safety changes in pain intensity, blood pressure, plasma renin activity, changes in laboratory markers, QOL | 70/18–55 years | New York Medical College | Oral, twice daily for 1 year vs. placebo | NCT03719729 (IMRA study) | Enrolling by invitation | Recruiting | NCT03758950 (SCOT study) |
| Vasodilator | Arginine | Phase II | Safety, change in fetal hemoglobin, HbA2c, reticulocyte count, serum retinol, measures | 70/18–55 years | Augusta University | Intravenous, three times a day vs. placebo | NCT00538030 (IMRA study) | Open-label extension | Recruiting | NCT02712346 (IMRA study) |
| Anti-inflammatory | Docosahexaenoic acid (endothelin receptor A antagonist) | Phase II | Safety, change in pain intensity, blood pressure, plasma renin activity, changes in laboratory markers, QOL | 70/18–55 years | Augusta University | Intravenous, three times a day vs. placebo | NCT00538030 (IMRA study) | Open-label extension | Recruiting | NCT02712346 (IMRA study) |
| Anti-inflammatory | Docosahexaenoic acid (anti-IL1β antibody) | Phase II | Safety, change in pain intensity, blood pressure, plasma renin activity, changes in laboratory markers, QOL | 70/18–55 years | Thomas Jefferson University | Oral, daily 12 weeks vs. placebo | NCT01202812 (TASC) | Active, not recruiting | Recruiting | NCT02447874 (IMR-687) |
| Anti-inflammatory | Docosahexaenoic acid (anti-LA antibody) | Phase II | Safety, change in pain intensity, blood pressure, plasma renin activity, changes in laboratory markers, QOL | 70/18–55 years | New York Medical College | Oral, daily for 24 weeks vs. placebo | NCT03615924 (IMRA study) | Enrolling by invitation | Recruiting | NCT03758950 (SCOT study) |
| Anti-inflammatory | Docosahexaenoic acid (soluble guanylate cyclase stimulator) | Phase II | Safety, change in pain intensity, blood pressure, plasma renin activity, changes in laboratory markers, QOL | 70/18–55 years | Mark Gladwin | Intravenous, three times a day vs. placebo | NCT01202812 (TASC) | Active, not recruiting | Recruiting | NCT02447874 (IMR-687) |
| Anti-inflammatory | Docosahexaenoic acid (selective phosphodiesterase-9 inhibitor) | Phase II | Safety, change in pain intensity, blood pressure, plasma renin activity, changes in laboratory markers, QOL | 70/18–55 years | Augusta University | Intravenous, three times a day vs. placebo | NCT00538030 (IMRA study) | Open-label extension | Recruiting | NCT02712346 (IMRA study) |
| Anti-inflammatory | Docosahexaenoic acid (selective phosphodiesterase-9 inhibitor) | Phase II | Safety, change in pain intensity, blood pressure, plasma renin activity, changes in laboratory markers, QOL | 70/18–55 years | Augusta University | Intravenous, three times a day vs. placebo | NCT00538030 (IMRA study) | Open-label extension | Recruiting | NCT02712346 (IMRA study) |
| Anti-inflammatory | Docosahexaenoic acid (soluble guanylate cyclase stimulator) | Phase II | Safety, change in pain intensity, blood pressure, plasma renin activity, changes in laboratory markers, QOL | 70/18–55 years | Mark Gladwin | Intravenous, three times a day vs. placebo | NCT01202812 (TASC) | Active, not recruiting | Recruiting | NCT02447874 (IMR-687) |
| Anti-inflammatory | Docosahexaenoic acid (endothelin receptor A antagonist) | Phase II | Safety, change in pain intensity, blood pressure, plasma renin activity, changes in laboratory markers, QOL | 70/18–55 years | Augusta University | Intravenous, three times a day vs. placebo | NCT00538030 (IMRA study) | Open-label extension | Recruiting | NCT02712346 (IMRA study) |
| Anti-inflammatory | Docosahexaenoic acid (anti-LA antibody) | Phase II | Safety, change in pain intensity, blood pressure, plasma renin activity, changes in laboratory markers, QOL | 70/18–55 years | New York Medical College | Oral, daily 12 weeks vs. placebo | NCT03615924 (IMRA study) | Enrolling by invitation | Recruiting | NCT03758950 (SCOT study) |
| Anti-inflammatory | Docosahexaenoic acid (soluble guanylate cyclase stimulator) | Phase II | Safety, change in pain intensity, blood pressure, plasma renin activity, changes in laboratory markers, QOL | 70/18–55 years | Mark Gladwin | Intravenous, three times a day vs. placebo | NCT01202812 (TASC) | Active, not recruiting | Recruiting | NCT02447874 (IMR-687) |
| Anti-inflammatory | Docosahexaenoic acid (selective phosphodiesterase-9 inhibitor) | Phase II | Safety, change in pain intensity, blood pressure, plasma renin activity, changes in laboratory markers, QOL | 70/18–55 years | Augusta University | Intravenous, three times a day vs. placebo | NCT00538030 (IMRA study) | Open-label extension | Recruiting | NCT02712346 (IMRA study) |
| Anti-inflammatory | Docosahexaenoic acid (endothelin receptor A antagonist) | Phase II | Safety, change in pain intensity, blood pressure, plasma renin activity, changes in laboratory markers, QOL | 70/18–55 years | Augusta University | Intravenous, three times a day vs. placebo | NCT00538030 (IMRA study) | Open-label extension | Recruiting | NCT02712346 (IMRA study) |
| Anti-inflammatory | Docosahexaenoic acid (selective phosphodiesterase-9 inhibitor) | Phase II | Safety, change in pain intensity, blood pressure, plasma renin activity, changes in laboratory markers, QOL | 70/18–55 years | Augusta University | Intravenous, three times a day vs. placebo | NCT00538030 (IMRA study) | Open-label extension | Recruiting | NCT02712346 (IMRA study) |

ACS, acute chest syndrome; HbF, fetal hemoglobin; HS-CRP, high-sensitivity C-reactive protein; NO, nitric oxide; NT-proBNP, N-terminal pro-BNP; TASC, vascular cell adhesion molecule-1; VOC, vaso-occlusive crisis; vWF, von Willebrand factor.
to moderate acute chest syndrome\textsuperscript{136}. However, L-arginine, an NO precursor, significantly decreased total parenteral opioid use and pain scores at discharge compared to placebo in children, although there was no difference in length of hospital stay\textsuperscript{137}. Furthermore, supplementation of adult patients on hydroxyurea with oral arginine significantly increased the level of NO metabolites and reduced the frequency of pain crises versus placebo following 4 months of treatment\textsuperscript{138}. Sildenafil, a phosphodiesterase-5 inhibitor which increases NO-mediated effects by inhibiting the degradation of cyclic guanosine monophosphate (cGMP), was associated with more frequent serious adverse events, predominantly hospitalization for pain, compared with placebo\textsuperscript{139}. No evidence of a treatment effect of sildenafil was seen on evaluated study outcomes. Studies of soluble guanylate cyclase stimulators, riociguat (NCT02633397) and olinciguat/IW-1701 (NCT03285178), and the phosphodiesterase-9 inhibitor IMR-687 (NCT03401112; NCT04053803) are ongoing (Table 3).

**Summary**

Recent advances in drug development for SCD raise important issues related to the use and availability of these agents. With limited availability of allogeneic bone marrow transplantation and gene therapy, especially in low- and middle-income countries, the number of recently approved drugs offers hope for further improved outcomes in SCD. Choice of initial drug therapy may be guided by a patient’s clinical sub-phenotype as well as the cost of the drug (Table 4). Patients with frequent vaso-occlusive complications (acute pain episodes, acute chest syndrome) may benefit from hydroxyurea, L-glutamine, and crizanlizumab, while those with increased hemolytic anemia (or quite possibly complications related to hemolytic anemia) may benefit from

---

**Table 4. Summary characteristics of FDA-approved drugs for sickle cell disease.**

|                     | Hydroxyurea | L-Glutamine | Crizanlizumab | Voxelotor |
|---------------------|-------------|-------------|---------------|-----------|
| **Age (years)**     | ≥2          | ≥5          | ≥16           | ≥12       |
| **Genotypes**       | HbSS, HbSβ\textsuperscript{a} thalassemia | All genotypes (only studied in HbSS, HbSβ\textsuperscript{a} thalassemia) | All genotypes | All genotypes |
| **Mechanism of action** | Multiple, but primarily by increasing HbF production | Uncertain, but thought to reduce NAD redox potential, possible decrease in cell adhesion | Anti P-selectin inhibitor (decreases adhesion of WBCs and RBCs to endothelium) | Decreases HbS polymerization by increasing Hb-oxygen affinity |
| **Route of administration** | Oral (capsules/tablets) | Oral (powder) | Intravenous | Oral (tablets) |
| **Clinical effects of therapy** | Decreased frequency of VOC, decreased frequency of ACS, decreased RBC transfusion requirement, decreased stroke risk | Decreased frequency of VOC, decreased frequency of ACS, decreased hospitalization | Decreased frequency of VOC | Increased hemoglobin |
| **Effect size for primary endpoint (% change and IRR)** | 44% decrease in VOC per year (median from 4.5 to 2.5), IRR = 0.56 | 25% decrease in VOC in 48 weeks (median from 4 to 3), IRR = 0.75 | 45% decrease in crisis rate per year (median from 3 to 1.6), IRR = 0.55 | 5.5-fold increase in the hemoglobin responders (9% to 59%) at 24 weeks, incidence proportion ratio = 6.6\textsuperscript{*} |
| **Common toxicities** | Myelosuppression, skin hyperpigmentation, nail discoloration, teratogenicity, decreased sperm counts, nausea and vomiting | Constipation, nausea, headaches, abdominal pain | Nausea, arthralgia | Headache, diarrhea, nausea |
| **Pharmacokinetics** | Excreted via kidneys Adjust dose for eGFR <60 mL/min/1.73 m\textsuperscript{2} | Use with caution with hepatic and renal impairment, but no recommended dose adjustment | No dosage adjustments in manufacturer labeling for renal and hepatic impairment (not tested in ESRD) | No dosage adjustment for renal impairment, but not yet studied in ESRD requiring dialysis Dose reduction for severe liver disease (Child Pugh class C) |
| **Cost**            | $           | $$$         | $$$$$        | $$$$$    |

ACS, acute chest syndrome; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; FDA, US Food and Drug Administration; Hb, hemoglobin; HbF, fetal hemoglobin; HbS, sickle hemoglobin; IRR, incidence rate ratio; NAD, nicotinamide adenine dinucleotide; RBC, red blood cell; VOC, vaso-occlusive crisis; WBC, white blood cell.

* Patients treated with 1,500 mg of voxelotor had 6.6 times increased proportion of hemoglobin responders (>1 g/dL increase from baseline at 24 weeks)
hydroxyurea and voxelotor. However, more studies are required before definite recommendations can be made regarding the effect of voxelotor on SCD-related complications. As with other chronic disease conditions, it is important to consider the cost of the drug when deciding on initial therapy. Hydroxyurea is much cheaper than L-glutamine, crizanlizumab, and voxelotor and is likely more cost effective as initial therapy for vaso-occlusive complications and hemolytic anemia. However, with the complex pathophysiology of SCD and the limited clinical efficacy of available pharmacological therapies, it is unlikely that a single drug will ameliorate all SCD-related complications. As such, the availability of multiple drugs offers an opportunity for combination therapy based on different mechanisms of action and non-overlapping side effect profiles. Although more studies are required to evaluate the effect of combinations of these drugs, all of the recently approved agents were tested in combination with hydroxyurea. These studies showed benefit whether or not participants received concomitant hydroxyurea, with no increased toxicity. Despite potential benefits, combination therapy involving the use of multiple drugs increases the likelihood of decreased medication adherence owing to polypharmacy. Like in other chronic diseases, however, this problem may be somewhat ameliorated by the development of pills that contain more than one active drug.

It is particularly important that ongoing trials of novel drugs for SCD involve individuals in resource-limited countries where the burden of disease is high. This offers patients access to potentially disease-modifying therapies but, perhaps equally as important, contributes substantially to capacity building by improving local infrastructure, strengthening health systems, involving local leaders as collaborators, and training local providers. Furthermore, trials of novel agents in sub-Saharan Africa provide data on the effects of these therapies in a setting with fewer resources and unique challenges, including a high prevalence of malnutrition and infections such as malaria. With the high cost of recently approved agents, mechanisms to ensure affordable access to these drugs should be established. A situation where novel agents are tested in resource-limited countries but patients in these countries are unable to afford such drugs following approval is unacceptable. Finally, studies evaluating the effects of recently approved drugs on organ damage are needed. Demonstration that these agents prevent or decrease end-organ damage would provide additional evidence for the role of drug therapies in improving outcomes in SCD.

Acknowledgements

The authors thank Dr. Joacy Gerard Matthews and Dr. Matthew P. Smeltzer (Both from the Division of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, University of Memphis, Memphis, Tennessee, USA) for helping to ascertain the drug effect sizes.
42. Dehury S, Purohit P, Patel S, et al.: Low and Fixed Dose of Hydroxyurea Is Effective and Safe in Patients With HbS(α) Thalassemia With IVS1-5G→C Mutation. Pediatr Blood Cancer. 2015; 62(8): 1017–23.

43. Jain DL, Apte M, Cohal R, et al.: Efficacy of Fixed Low Dose Hydroxyurea in Indian Children With Sickle Cell Anemia: A Single Centre Experience. Indian Pediatr. 2015; 52(10): 929–33.

44. Waren RE, Davis BR, Schultz WH, et al.: Hydroxyurea Versus Chronic Transfusion for Maintenance of Transcranial Doppler Flow Velocities in Children With Sickle Cell Anemia-TCD With Transfusions Changing to Hydroxyurea (TITCH): A Multicentre Open-Label, Phase 3, Non-Inferiority Trial. Lancet. 2016; 387(10019): 661–70.

45. Lobo CD, Pinto JFC, Nascimento EM, et al.: The Effect of Hydroxyurea Treatment on Survival of Children With Sickle Cell Disease. Br J Haematol. 2013; 164(6): 852–60.

46. Steinberg MH, Barton F, Castro O, et al.: Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment. JAMA. 2003; 289(13): 1645–51.

47. Wang WC, Ware RE, Miller ST, et al.: Hydroxyurea in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BASHLY HUG), Lancet. 2011; 377(9771): 1663–72.

48. Wang WC, Ware RE, Miller ST, et al.: Hydroxyurea in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BASHLY HUG), Lancet. 2011; 377(9771): 1663–72.

49. Wang WC, Ware RE, Miller ST, et al.: Hydroxyurea in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BASHLY HUG), Lancet. 2011; 377(9771): 1663–72.

50. Wang WC, Ware RE, Miller ST, et al.: Hydroxyurea in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BASHLY HUG), Lancet. 2011; 377(9771): 1663–72.

51. Wang WC, Ware RE, Miller ST, et al.: Hydroxyurea in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BASHLY HUG), Lancet. 2011; 377(9771): 1663–72.

52. Wang WC, Ware RE, Miller ST, et al.: Hydroxyurea in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BASHLY HUG), Lancet. 2011; 377(9771): 1663–72.

53. Wang WC, Ware RE, Miller ST, et al.: Hydroxyurea in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BASHLY HUG), Lancet. 2011; 377(9771): 1663–72.

54. Wang WC, Ware RE, Miller ST, et al.: Hydroxyurea in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BASHLY HUG), Lancet. 2011; 377(9771): 1663–72.

55. Wang WC, Ware RE, Miller ST, et al.: Hydroxyurea in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BASHLY HUG), Lancet. 2011; 377(9771): 1663–72.

56. Wang WC, Ware RE, Miller ST, et al.: Hydroxyurea in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BASHLY HUG), Lancet. 2011; 377(9771): 1663–72.

57. Wang WC, Ware RE, Miller ST, et al.: Hydroxyurea in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BASHLY HUG), Lancet. 2011; 377(9771): 1663–72.

58. Wang WC, Ware RE, Miller ST, et al.: Hydroxyurea in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BASHLY HUG), Lancet. 2011; 377(9771): 1663–72.

59. Wang WC, Ware RE, Miller ST, et al.: Hydroxyurea in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BASHLY HUG), Lancet. 2011; 377(9771): 1663–72.

60. Wang WC, Ware RE, Miller ST, et al.: Hydroxyurea in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BASHLY HUG), Lancet. 2011; 377(9771): 1663–72.

61. Wang WC, Ware RE, Miller ST, et al.: Hydroxyurea in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BASHLY HUG), Lancet. 2011; 377(9771): 1663–72.

62. Wang WC, Ware RE, Miller ST, et al.: Hydroxyurea in Very Young Children With Sickle-Cell Anaemia: A Multicentre, Randomised, Controlled Trial (BASHLY HUG), Lancet. 2011; 377(9771): 1663–72.
with sickle cell disease who have not benefitted from hydroxyurea. Biol. 2015; 128(3): 3669–9.
Published Abstract | Publisher Full Text | Free Full Text
63. Reed ME, El Beshawy A, Inati A, et al.: A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HGK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2019; 94(7): 709–13.
Published Abstract | Publisher Full Text | Faculty Opinions Recommendation
64. Sneader JR, Golontzka O, Churakai A, et al.: Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2. PLoS One. 2016; 11:e0153767.
Published Abstract | Publisher Full Text | Free Full Text
65. Rivers A, Vaiitis K, Jagadeeswaran R, et al.: Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons. Exp Hematol. 2018; 67: 69–64.e2.
Published Abstract | Publisher Full Text | Faculty Opinions Recommendation
66. Meiler SE, Wade M, Kutlar F, et al.: Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. Biol. 2011; 118(4): 1109–12.
Published Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation
67. Kutlar A, Swerdlow PS, Meiler SE, et al.: Pomalidomide In Sickle Cell Disease: Phase I Study Of A Novel Anti-Switching Agent. Blood. 2013; 122(1): 777.
Published Full Text
68. Zhang Y, Pakkan A, Sumazin P, et al.: Metformin induces FOXO3-dependent fetal hemoglobin production in human primary erythroid cells. Biol. 2018; 132(3): 321–33.
Published Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation
69. Krishnamoorthy S, Pace B, Gupta D, et al.: Dimethyl fumarate increases fetal hemoglobin, provides heme detoxification, and corrects anemia in sickle cell disease. JCI Insight. 2017; 2(20): e96409.
Published Abstract | Publisher Full Text | Free Full Text
70. Dai Y, Chen T, Iaz H, et al.: SIRT7 activates the expression of fetal hemoglobin genes. Am J Hematol. 2017; 92(1): 1177–1186.
Published Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation
71. Oksenberg D, Dufu K, Patel M, et al.: GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. Br J Haematol. 2016; 175(1): 141–53.
Published Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation
72. Dufu K, Patel M, Oksenberg D, et al.: GBT440 improves red blood cell deformability and reduces viscosity of sickle cell blood under deoxygenated conditions. Clin Hemorheol Microcirc. 2018; 70(1): 95–103.
Published Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation
73. Vichinsky E, Hoppe CC, Ataga KI, et al.: A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019; 381(6): 509–519.
Published Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation
74. Kato GJ, Lawrence MP, Mendelsohn LG, et al.: Phase 1 Clinical Trial Of The Candidate Anti-Sickling Agent Aes-103 In Adults With Sickle Cell Anemia. Blood. 2013; 122: 1009.
Published Full Text
75. Kufs FA, Telen MJ, et al.: Phase I Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase R, in Healthy and Sickle Cell Disease Subjects. Blood. 2019; 134(Supplement 1): 616.
Published Full Text
76. Belcher JD, Young M, Chen C, et al.: MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of Hb-1, inflammation, and vaso-occlusion in transgenic sickle mice. Blood. 2013; 122(15): 2575–64.
Published Abstract | Publisher Full Text | Free Full Text
77. Abruchova A: SANGUINATE (PEGylated Carboxyhemoglobin Bovine): Mechanism of Action and Clinical Update. Ant fibrin. Organs. 2017; 41(4): 346–350.
Published Abstract | Publisher Full Text | Free Full Text
78. Keipert PE: Clinical Evaluation of MP4CO: A Phase 1b Escalating-Dose, Safety and Tolerability Study in Stable Adult Patients with Sickle Cell Disease. Adv Exp Med Biol. 2016; 923: 23–29.
Published Abstract | Publisher Full Text | Free Full Text
79. Misra H, Bainbridge J, Berryman J, et al.: A Phase Ib open label, randomized, safety study of SANGUINATE™ in patients with sickle cell anemia. Rev Bras Hematol Mol Hemat. 2017; 39(1): 20–27.
Published Abstract | Publisher Full Text | Free Full Text
80. Sunshine HR, Hofrichter J, Eaton WA: Requirement for therapeutic inhibition of sickle hemoglobin gelation. Nature. 1978; 276(5677): 238–40.
Published Abstract | Publisher Full Text | Free Full Text
81. Ataga KI, Reid M, Ballas SK, et al.: Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: A phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Br J Haematol. 2011; 153(1): 92–104.
Published Abstract | Publisher Full Text | Free Full Text
82. Ataga KI, Smith WR, de Castro LM, et al.: Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Biol. 2008; 111(8): 3991–7.
Published Abstract | Publisher Full Text | Free Full Text
83. Broussseau DC, Scott JP, Badal-Makan O, et al.: A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Biol. 2015; 126(14): 1651–7.
Published Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation
84. Goldman RD, Mountschen W, Kidney-Me M, et al.: Intravenous magnesium sulfate for vaso-occlusive episodes in sickle cell disease. Pediatrics. 2013; 132(6): e1634–41.
Published Abstract | Publisher Full Text | Free Full Text
85. de Franceschi L, Bachir D, Galacteros F, et al.: Oral magnesium pidolate: Effects of long-term administration in patients with sickle cell disease. Br J Haematol. 2000; 108(2): 284–9.
Published Abstract | Publisher Full Text | Free Full Text
86. Swift R, Abdaline M, Chen Q, et al.: SCD-101: A New Anti-Sickling Drug Reduces Pain and Fatigue and Improves Red Blood Cell Shape in Peripheral Blood of Patients with Sickle Cell Disease. Biol. 2016; 128(22): 121.
Published Full Text
87. Hirahara Y, Smith WR, Stark CW: A Phase 3 Trial of I-Glutamine in Sickle Cell Disease. N Engl J Med. 2018; 379(19): 1880.
Published Abstract | Publisher Full Text | Faculty Opinions Recommendation
88. Nur E, Brandjes DP, Teekink T, et al.: N-acetylcysteine reduces oxidative stress in sickle cell patients. Am J Hematol. 2012; 91(7): 1097–105.
Published Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation
89. Orringer EP, Cassella JF, Ataga KI, et al.: Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. JAMA. 2001; 286(17): 2093–106.
Published Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation
90. https://www.prnewswire.com/news-releases/mast-therapeutics-reports-top-line-results-from-phase-3-study-in-sickle-cell-disease-300311289.html
91. Chang J, Patton JT, Sarkar A, et al.: GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Biol. 2010; 116(10): 1773–86.
Published Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation
92. Telen MJ, Winder T, McCaw TL, et al.: Randomized phase 2 study of GMI-1070 in SCD: Reduction in time to resolution of vaso-occlusive events and decreased opioid use. Biol. 2015; 125(17): 2656–64.
Published Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation
93. https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_phase_3_top_line_results_for_rivpasinel_in_patients_with_sickle_cell_disease_experiencing_a_vaso_occlusive_crisis
94. Matsui NM, Van Y, Embury SH: Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Biol. 2002; 70(10): 3790–9.
Published Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation
95. Embury SH, Matsui NM, Ramanujam S, et al.: The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo. Biol. 2004; 104(10): 3378–85.
Published Abstract | Publisher Full Text | Free Full Text | Faculty Opinions Recommendation
96. Qin MH, Aliaiouni SK, Aalardawi MS, et al.: Reduction of Painful Vaso-occlusive Crisis of Sickle Cell Anemia by Tinzaparin in a Double-blind Randomized Trial. Thromb Haematol. 2017; 98(2): 392–8.
Published Abstract | Publisher Full Text | Free Full Text
97. Telen MJ, Batchvarova M, Shan S, et al.: Sevuparin Binds to Multiple Adhesive Ligands and Reduces Sickle Red Blood Cell-Induced Vaso-occlusion. Br J
Open Peer Review

Current Peer Review Status: ✔

Editorial Note on the Review Process

Faculty Reviews are written by members of the prestigious Faculty Opinions Faculty. They are commissioned and are peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. Yogen Saunthararajah
   Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
   Competing Interests: YS has patents, owns equity in, and serves on the board of a company EpiDestiny that is developing drug therapy for sickle cell disease.

2. Daniel E. Bauer
   1 Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA
   2 Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
   3 Department of Pediatrics, Harvard Medical School, Boston, MA, USA
   Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

• Your article is published within days, with no editorial bias
• You can publish traditional articles, null/negative results, case reports, data notes and more
• The peer review process is transparent and collaborative
• Your article is indexed in PubMed after passing peer review
• Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com